SR34006 Compared to Vitamin K Antagonist (VKA) in the Treatment of Pulmonary Embolism
Status:
Completed
Trial end date:
2005-10-01
Target enrollment:
Participant gender:
Summary
Patients who have a pulmonary embolism (blood clot in the lung) will be treated in this
study. The purpose of the study is to compare the safety and effectiveness of a new
injectable anticoagulant (blood-thinning) drug, SR34006, with the standard way of treating a
pulmonary embolism. The standard treatment includes injections or infusions of an
anticoagulant drug, (LMW)heparin, for about a week followed by anticoagulant tablets
(warfarin or acenocoumarol) which are taken by mouth.
Assignment to either SR34006 or (LMW)heparin plus warfarin or acenocoumarol will be purely by
chance and will be known by both patients and their doctors.
Phase:
Phase 3
Details
Lead Sponsor:
Sanofi
Treatments:
Acenocoumarol Calcium heparin Heparin SANORG 34006 Vitamin K Warfarin